US advisory report warns of reliance on China for medicines

Illustration for: US advisory report warns of reliance on China for medicines
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

THE BARE STORY

A bipartisan advisory body to the US Congress warned in a report released on Nov. 19 that the United States could become increasingly dependent on China for life-saving medicines, creating a risk of supply disruptions.

The National Security Commission on Emerging Biotechnology analyzed 57 transactions between 42 Chinese biotechnology firms and 15 major pharmaceutical companies operating in the United States, from early 2023 through October 2026. It said collaborations were increasingly taking place at earlier stages of drug development, often through licensing agreements.

The commission said the agreements provide Chinese firms with capital and commercialization expertise, while potentially weakening US biotechnology research capabilities. It warned that Chinese dominance over particular medicines or ingredients could lead to shortages.

The report identified proposed restrictions on US investment in Chinese biotechnology as a step toward addressing the issue.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.

Stories You May Have Missed